Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

30.25
Delayed Data
As of 4:00pm ET
 0.00 / 0.00%
Today’s Change
18.55
Today|||52-Week Range
245.82
-70.24%
Year-to-Date
Billionaire Showdown: Is Valeant Pharmaceuticals International Worth the Risk?
1:45pm / MotleyFool.com - Paid Partner Content
Healthcare Winners: Stryker Corp., UnitedHealth Group Inc.
Aug 29 / GuruFocus News - Paid Partner Content
Big Pharma's Punishment in Court of Public Opinion
11:39am / TheStreet.com - Paid Partner Content
Bill Ackman Comments on Valeant
Aug 29 / GuruFocus News - Paid Partner Content
2 Biotechs to Watch Ahead of the Election
10:07am / TheStreet.com - Paid Partner Content
Pharma Has History of Price Gouging, Mylan Should Be No Surprise
Aug 26 / TheStreet.com - Paid Partner Content
Big Pharma Has No Rx for Viral Social Media Reactions
9:42am / TheStreet.com - Paid Partner Content
Bill Ackman: Valeant 'One Very Big Mistake'
Aug 26 / GuruFocus News - Paid Partner Content
Valeant (VRX) Stock Falls on Lawsuit
Aug 29 / TheStreet.com - Paid Partner Content
Forget Mylan, Buy These 3 Drug Stocks Instead
Aug 26 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close30.25
Today’s open29.88
Day’s range29.71 - 30.64
Volume17,088,132
Average volume (3 months)31,203,865
Market cap$10.3B
Dividend yield--
Data as of 4:00pm ET, 08/30/2016

Growth & Valuation

Earnings growth (last year)-131.25%
Earnings growth (this year)-35.41%
Earnings growth (next 5 years)+11.00%
Revenue growth (last year)+26.42%
P/E ratioNM
Price/Sales3.32
Price/Book1.75

Competitors

 Today’s
change
Today’s
% change
MNKMallinckrodt Plc+0.85+1.15%
PRGOPerrigo Company PLC+1.98+2.22%
RDYDr.Reddy's Laborator...+0.49+1.07%
JAZZJazz Pharmaceuticals...-0.50-0.39%
Data as of 4:02pm ET, 08/30/2016

Financials

Next reporting dateOctober 17, 2016
EPS forecast (this quarter)$1.80
Annual revenue (last year)$10.4B
Annual profit (last year)-$291.7M
Net profit margin-2.79%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
Joseph C. Papa
Chief Financial Officer &
Executive VP-Finance
Paul S. Herendeen
Corporate headquarters
Laval, Quă©bec

Forecasts

Search for Jobs